文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

不同估算肾小球滤过率公式对危重症成人美罗培南药代动力学的影响

Impact of Various Estimated Glomerular Filtration Rate Equations on the Pharmacokinetics of Meropenem in Critically Ill Adults.
PubMed 文献 · Crit Care Explor · 2023-12-14
一句话结论在危重症成人中,联合肌酐与胱抑素C的eGFR公式较单用任一指标更能改善美罗培南群体药代动力学模型效能。

本研究为单中心研究,纳入2018至2022年ICU接受静脉美罗培南的成人,排除急性肾损伤、肾脏替代治疗或体外膜肺氧合患者。采用丰富采样开发队列(n=19)建立二室模型,机会采样验证队列(n=32)评估。最终模型以时间依赖体重(归一化至70 kg成人)为分布容积协变量、时间依赖eGFR为清除率协变量;基于肌酐与胱抑素C的eGFR(mL/min)最佳预测美罗培南清除率。最终模型平均分布容积18.2 L(SE 3.5),清除率11.5 L/hr(SE 1.3);以开发队列为贝叶斯先验,验证队列显示良好准确度和低偏倚。

要点

  • 在危重症成人中,联合肌酐与胱抑素C的eGFR公式较单用肌酐或单用胱抑素C的eGFR公式更能改善美罗培南群体药代动力学模型效能。
  • 最终模型以时间依赖体重(归一化至70 kg成人)为分布容积协变量、时间依赖eGFR为清除率协变量,基于肌酐与胱抑素C的eGFR(mL/min)最佳预测美罗培南清除率。
  • 最终模型平均分布容积18.2 L(SE 3.5),清除率11.5 L/hr(SE 1.3)。
  • 以开发队列为贝叶斯先验,机会采样验证队列显示良好准确度和低偏倚。
  • 研究排除急性肾损伤、肾脏替代治疗或体外膜肺氧合患者,结果不直接适用于这些人群。

适用人群与场景

  • 2018至2022年ICU住院并接受静脉美罗培南的成人。
  • 排除急性肾损伤、接受肾脏替代治疗或接受体外膜肺氧合的患者。

研究设计与关键结果

  • 单中心研究,采用丰富采样开发队列(n=19)和机会采样验证队列(n=32)进行群体药代动力学建模。
  • 最佳拟合结构模型为二室模型,一级消除。
  • 最终模型以时间依赖体重(归一化至70 kg成人)为分布容积协变量、时间依赖eGFR为清除率协变量;基于肌酐与胱抑素C的eGFR(mL/min)最佳预测美罗培南清除率。
  • 最终模型平均分布容积18.2 L(SE 3.5),清除率11.5 L/hr(SE 1.3)。
  • 以开发队列为贝叶斯先验,机会采样验证队列显示良好准确度和低偏倚。

证据类型、等级与局限

  • 证据类型:单中心群体药代动力学建模研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在成人危重症患者中,使用同时包含肌酐和胱抑素C的当代eGFR公式可改善美罗培南群体药代动力学模型效能,优于仅用肌酐或仅用胱抑素C的eGFR公式。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Meropenem dosing is typically guided by creatinine-based estimated glomerular filtration rate (eGFR), but creatinine is a suboptimal GFR marker in the critically ill.

OBJECTIVES: This study aimed to develop and qualify a population pharmacokinetic model for meropenem in critically ill adults and to determine which eGFR equation based on creatinine, cystatin C, or both biomarkers best improves model performance.

DESIGN SETTING AND PARTICIPANTS: This single-center study evaluated adults hospitalized in an ICU who received IV meropenem from 2018 to 2022. Patients were excluded if they had acute kidney injury, were on kidney replacement therapy, or were treated with extracorporeal membrane oxygenation. Two cohorts were used for population pharmacokinetic modeling: a richly sampled development cohort (n = 19) and an opportunistically sampled qualification cohort (n = 32).

MAIN OUTCOMES AND MEASURES: A nonlinear mixed-effects model was developed using parametric methods to estimate meropenem serum concentrations.

RESULTS: The best-fit structural model in the richly sampled development cohort was a two-compartment model with first-order elimination. The final model included time-dependent weight normalized to a 70-kg adult as a covariate for volume of distribution (Vd) and time-dependent eGFR for clearance. Among the eGFR equations evaluated, eGFR based on creatinine and cystatin C expressed in mL/min best-predicted meropenem clearance. The mean (se) Vd in the final model was 18.2 (3.5) liters and clearance was 11.5 (1.3) L/hr. Using the development cohort as the Bayesian prior, the opportunistically sampled cohort demonstrated good accuracy and low bias.

CONCLUSIONS AND RELEVANCE: Contemporary eGFR equations that use both creatinine and cystatin C improved meropenem population pharmacokinetic model performance compared with creatinine-only or cystatin C-only eGFR equations in adult critically ill patients.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Barreto EF, Chang J, Rule AD, et al. Impact of Various Estimated Glomerular Filtration Rate Equations on the Pharmacokinetics of Meropenem in Critically Ill Adults. Crit Care Explor. 2023. PMID: 38107538. doi:10.1097/CCE.0000000000001011

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。